Back to top
more

SESEN BIO, INC. (SESN)

(Delayed Data from NSDQ)

$1.30 USD

1.30
2,172,114

+0.07 (5.69%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.30 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth

by Zacks Equity Research

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers

by Zacks Equity Research

Following FDA approval for label expansion, Vertex Pharmaceuticals' (VRTX) Orkambi is now approved for treating cystic fibrosis in children aged one year and older.

AstraZeneca (AZN) Evusheld Gets Japan Nod as COVID Treatment

by Zacks Equity Research

AstraZeneca's (AZN) Evusheld gets approval in Japan for treating COVID-19. This is the first global approval for Evusheld as a COVID-19 treatment.

Sanofi (SNY) Hemophilia A Drug BLA Gets FDA Priority Tag

by Zacks Equity Research

Sanofi's (SNY) BLA filing for efanesoctocog alfa was based on data from the XTEND-1 pivotal phase III study.

    Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%

    by Zacks Equity Research

    After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.

    BioMarin's (BMRN) Hemophilia Gene Therapy Gets Nod in EU

    by Zacks Equity Research

    BioMarin's (BMRN) Roctavian is the first gene therapy to get approval for hemophilia A in the European Union. The therapy has also been granted a 10-year market exclusivity.

    SESEN BIO, INC. (SESN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

    by Zacks Equity Research

    After losing some value lately, a hammer chart pattern has been formed for SESEN BIO, INC. (SESN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

    Jazz (JAZZ) Starts Study on Epidiolex for a Fourth Indication

    by Zacks Equity Research

    Jazz Pharmaceuticals (JAZZ) initiates a two-part pivotal late-stage study evaluating its epilepsy drug, Epidiolex, in children and adolescents suffering from epilepsy with Myoclonic-Atonic Seizures (EMAS).

    I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal

    by Zacks Equity Research

    I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.

    Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

    by Zacks Equity Research

    Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.

    Best Momentum Stocks to Buy for August 15th

    by Zacks Equity Research

    BRT, ERJ, and SESN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2022.

    Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

    by Zacks Equity Research

    Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

    Reata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down

    by Zacks Equity Research

    Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.

    Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

    by Zacks Equity Research

    Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.

    Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat

    by Zacks Equity Research

    Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.

    What's in the Cards for Sesen Bio's (SESN) Q2 Earnings?

    by Zacks Equity Research

    Sesen Bio's (SESN) Q2 performance is likely to reflect cost savings from the company's restructuring plans as the company continues to seek a potential partner for the further development of Vicineum.

    Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down

    by Zacks Equity Research

    Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.

    VERU's Shares Jump on Successful COVID-19 Study Results

    by Zacks Equity Research

    VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.

    Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why

    by Zacks Equity Research

    Despite no marketable drugs in its portfolio, Chinook (KDNY) is progressing well with its pipeline. Updated data from a study supports the potential clinical utility of BION-1301 in the IgA nephropathy indication.

    Merck (MRK) in Advanced Talks to Buy Seagen (SGEN) Per WSJ

    by Zacks Equity Research

    Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.

    Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies

    by Zacks Equity Research

    Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.

    AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline

    by Zacks Equity Research

    AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.

    Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints

    by Zacks Equity Research

    Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.

    Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA

    by Zacks Equity Research

    Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.

    Novartis (NVS) Announces Positive Data on Oncology Drug

    by Zacks Equity Research

    Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.